Seladelpar (Livdelzi, MBX-8025) — Research Compounds Library | RetatrutideCompare
Selective PPAR-δ agonist. FDA-approved in 2024 for primary biliary cholangitis in adults with inadequate UDCA response.
Selective PPAR-δ agonist. FDA-approved in 2024 for primary biliary cholangitis in adults with inadequate UDCA response.